Cognito Therapeutics' Spectris Shows EEG Biomarker Link to Alzheimer’s Outcomes
Event summary
- Cognito Therapeutics presented new data on its Spectris™ therapy at AD/PD™ 2026, showing EEG biomarker correlations with clinical outcomes in Alzheimer’s patients.
- The OVERTURE study found Spectris reduced EEG slowing, linked to slower cognitive decline and less brain volume loss.
- Spectris stimulation enhanced neural responses for working memory and cognitive processing in Alzheimer’s patients.
- EEG biomarkers from OVERTURE are being incorporated into the ongoing HOPE pivotal trial.
The big picture
Cognito’s findings suggest a potential breakthrough in using EEG biomarkers to track Alzheimer’s progression, which could accelerate neurotechnology adoption. The company’s focus on non-invasive, at-home therapies aligns with broader industry shifts toward patient-centric, scalable treatments for neurodegenerative diseases. Success in the HOPE trial could position Spectris as a key player in the Alzheimer’s treatment ecosystem.
What we're watching
- Biomarker Validation
- Whether EEG biomarkers can serve as reliable surrogate endpoints in Alzheimer’s trials.
- Clinical Translation
- The pace at which Spectris can transition from feasibility to pivotal trial success.
- Competitive Positioning
- How Cognito’s non-invasive approach differentiates it in the crowded Alzheimer’s therapeutic landscape.
Related topics